Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Receivables (2016 - 2021)

Historic Receivables for Ernexa Therapeutics (ERNA) over the last 12 years, with Q1 2021 value amounting to $24918.0.

  • Ernexa Therapeutics' Receivables fell 9349.4% to $24918.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $24918.0, marking a year-over-year decrease of 9349.4%. This contributed to the annual value of $112000.0 for FY2020, which is 9172.21% down from last year.
  • Latest data reveals that Ernexa Therapeutics reported Receivables of $24918.0 as of Q1 2021, which was down 9349.4% from $112000.0 recorded in Q4 2020.
  • Ernexa Therapeutics' 5-year Receivables high stood at $1.8 million for Q1 2017, and its period low was $24918.0 during Q1 2021.
  • In the last 5 years, Ernexa Therapeutics' Receivables had a median value of $732000.0 in 2019 and averaged $736406.9.
  • Per our database at Business Quant, Ernexa Therapeutics' Receivables surged by 14240.51% in 2020 and then plummeted by 9349.4% in 2021.
  • Ernexa Therapeutics' Receivables (Quarter) stood at $714000.0 in 2017, then surged by 137.39% to $1.7 million in 2018, then dropped by 20.18% to $1.4 million in 2019, then plummeted by 91.72% to $112000.0 in 2020, then plummeted by 77.75% to $24918.0 in 2021.
  • Its Receivables stands at $24918.0 for Q1 2021, versus $112000.0 for Q4 2020 and $132000.0 for Q3 2020.